Brain Metastases Management and Central Nervous System Activity

Dr. Kruse describes DESTINY-Breast12 as providing crucial reassuring data regarding T-DXd activity in patients with brain metastases. Previously, treatment decisions between tucatinib and T-DXd favored tucatinib for central nervous system (CNS) involvement due to stronger evidence from studies specifically designed to include patients with brain metastases. DESTINY-Breast12 addressed this gap by demonstrating meaningful activity across multiple endpoints including intracranial response rate, intracranial PFS, overall PFS, and OS.

The study challenges traditional assumptions about ADC penetration across the blood-brain barrier, whether related to HER2 targeting mechanisms or blood-brain barrier disruption in metastatic disease. Dr. Kruse emphasizes comfort using T-DXd for patients with brain metastases across treatment lines, including first-line therapy where brain metastases presence might actually favor T-DXd selection over other options due to demonstrated CNS activity.

Dr. Kang highlights the paradigm shift toward delaying local-regional therapy when systemic agents demonstrate high likelihood of CNS activity, providing powerful options for patients facing brain metastases. This represents a significant advancement in management approaches, allowing medical oncologists to feel confident about T-DXd's brain activity while acknowledging that DESTINY-Breast12 provided the definitive evidence supporting this clinical comfort level. The data enable more aggressive systemic approaches that may obviate or delay radiation therapy interventions.